Answers are grounded in this paper and cite their sources.
IL-10 + regulatory B cells (Bregs) play a significant role in cancer immunotherapy and their presence is an indicator of negative outcome. We found that PPARδ is significantly upregulated in tumor-induced IL-10 + Bregs with a phenotype of CD19 + CD24 hi IgD lo/− CD38 lo or CD19 + CD24 hi IgD lo/− CD38 hi in both mice and humans, and the level of PPARδ expression was correlated with their potential to produce IL-10 and to inhibit T cell activation. Genetic inactivation of PPARδ in B cells impaired the development and function of IL-10 + B cells, and treatment with PPARδ inhibitor diminished the induction of IL-10 + Bregs by tumor and CD40 engagement. Importantly, immunotherapy with anti-CD40 or anti-PD1 antibody achieved a markedly improved outcome in tumor-bearing mice with PPARδ deficiency in B cells or treated with PPARδ inhibitor. This study shows that PPARδ is required for the development and function of IL-10 + Bregs, providing a new and effective target for selectively blocking Bregs and improving antitumor immunotherapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: